Sana Biotechnology develops engineered cell therapies that repair and replace damaged or missing cells to address the root causes of diseases such as cancer, diabetes, and autoimmune disorders. By leveraging advanced gene editing techniques, the company aims to create targeted treatments that significantly improve patient outcomes.
Funding
$165M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many diseases, including cancer, diabetes, and autoimmune disorders, are caused by damaged, missing, or malfunctioning cells that current treatments often fail to address at the root cause. Traditional pharmaceutical approaches may only manage symptoms without repairing or replacing the underlying cellular damage.
Solution
Sana Biotechnology is developing engineered cell therapies designed to repair and replace damaged or missing cells, thereby addressing the fundamental causes of various diseases. The company leverages advanced gene editing technologies to create targeted treatments that can modify genes in cells or replace missing or damaged cells. These engineered cells act as medicines, offering the potential to meaningfully improve patient outcomes by targeting the cellular origins of disease. Sana's approach aims to deliver innovative drug candidates that can disrupt the course of diseases like cancer, diabetes, and autoimmune disorders.
Target Audience
The primary target audience includes patients suffering from diseases like cancer, diabetes, and autoimmune disorders, as well as healthcare providers seeking innovative and potentially curative treatment options.
Features
- Utilizes advanced gene editing techniques to modify cells for therapeutic purposes.
- Develops engineered cell therapies to replace missing or damaged cells.
- Focuses on treating diseases at their cellular origins, offering potential cures rather than just symptom management.
- Advances a pipeline of innovative drug candidates targeting cancer, diabetes, and autoimmune disorders.